That's what Vin said. So they have already picked it. My money's on lupus. Can you imagine a good drug for that disease? There will be BP partners pounding on the door.
During the presentation, Vinny told the story of how IDRA got started on their aggressive gene-targeting. He said a BOD member (no doubt Baker) was at a presentation given by the guy who discovered the gene mutation. During the pres, the guy stated that he thought TLR's were the way to defeat the gene. That BOD member took it to IDRA who "took it and ran with it"...starting WM , DLBCL trials, along with Dermatomysositis and any thing else that carries it. The diagnostic tool collaboration for the gene with Abbott was a brilliant early move.
With regards to GSO, there is plenty of room outside of oncology where 3rd gen will work miracles. Milano said they will consider licensing opportunities down the road, but that the bottom line is that they intend to build, own, and operate on their own. He also stated IDRA has all the pieces --- brilliant science with pioneers, best of the best investors, management with proven development and commercialization successes. He said some of that was lacking at Viropharm, and he was able to sell it anyway for 60/sh..
CEO called them VERY interested off ASH data. He described them as key members in critical development of not only oncology, but immuno-oncology. Don't over-analyze the collaborators label. It could mean a future partnership, but he said they were in discussions and expected to launch a Ph 1/2 trial in 6-9 mos with collaborator. So expect announcement a little earlier than that, perhaps ASCO.
You are correct, junk. 9200 is for broader condition with partner. Lupus fits perfectly.
I agree with 19 this year. Holding for long-term target 35-50 inside of 3 years. 8400 will be commercialized by then, and GSO will be awaiting Phase 3 results for multiple indications. Also, 9200 will be mowing down Lupus with a partner.
IDRA will be even bigger and badder long run. Congrats to all ACAD longs. I sold out and over to IDRA.
You won't hear anything more than catch phrases from daily short traders. The really dumb ones who hold their short position overnight will soon wake up to Breakthrough Designation status on the WM targeted oncogene. As we speak, patients in this trial who have tried EVERYTHING else, are having this gene annihilated. This translates to all diseases carrying this gene --- Burkitt's, DLBCL, Dermatomyositis, and more. There's a reason every manager, CEO, BOD member they bring on board immediately buys a million dollars worth of the stock. At this point, the shorts are our friends. When they knock it down, add large. It won't be under 5 long, and it will be a $50+ stock in 2-4 years.
Hilarious. I wish to remain unanimous as well. Let's take a vote and hope it's anonymous. LOL!!!!!!!!!!!!!
We are possibly less than a year from having patients as living testimony in WM trial. It is very specific gene that is being targeted. IDRA has spent millions in a partnership with Abbott to identify this gene in patients with DLBCL and other disorders. That's not something a smart management team would do if they didn't absolutely know the results IMO 8400 has on this gene. We will move significantly higher this year when WM breakthrough is announced.
Jackie, good post. I agree the climb will start here soon. The company is seeing WM results because it's open-label. They have just lured in Goldman and JPM, and that takes not just great persuasion, but documented evidence of exceptional science. These 2 firms do not ante up for 2-3 point gains. They get behind companies that are soon-to-be hugely successful. Follow the money and follow the science. When you start seeing loyal retail longs throwing in the towel, it's time to load. I'm expecting upgrades soon, and WM breakthrough updates as early as ASCO.
"Collectively, these data support advancing IMO-8400 into clinical development for the treatment of DMD (Duchenne's Muscular Dystrophy) patients.".............IDRA is marching on. The word is spreading slowly but surely.
None taken. GPRO peaked at 67 on earnings. Then got nailed hard from there. CERS will do good long run. IDRA will be the one that pulls a JAZZ/PCYC in the next 3 years. They've got it all. Don't listen to me unless it's IDRA :)
Yep. There were a couple large blocks last 1/2 hour, one for 150k shares. The AH is MM reconciling an earlier sell to fulfill the size of blocks like that. They see the whole board. In today's case, they took all the sells down to 4.25 and sold the accumulator 200k shares just like yesterday. Someone is buying large here and trying to stay quiet about it. Be interesting to see who the new holder is when 13g is filed.
"TLR9 agonists have demonstrated anti-tumor activity in combination with the checkpoint inhibitor ipilimumab, an anti-CTLA4 antibody marketed as Yervoy® by Bristol-Myers Squibb Company. In December 2014, we presented data at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Meeting from a preclinical study in which IMO-2055 delivered intratumorally in combination with ipilimumab demonstrated potent and systemic anti-tumor activity"...."We intend to initiate clinical development of either IMO-2055 or IMO-2125 in combination with these checkpoint inhibitors by submitting an investigational new drug application, or IND, for, and initiating, the first of two planned Phase 1/2 clinical trials in the second half of 2015."..........boatload of trials this year with some astounding results already in.
"IMO-9200 for Autoimmune Disease. We have developed a second novel synthetic oligonucleotide antagonist of TLR7, TLR8, and TLR9, IMO-9200, as a drug candidate in clinical development for potential use in selected autoimmune disease indications. In October 2014, we initiated subcutaneous dosing in a Phase 1 clinical trial of IMO-9200 in healthy subjects. We have also initiated additional preclinical studies of IMO-9200 for a selected autoimmune disease."...........LUPUS = Cha Ching and a partner
"We are currently undertaking an analysis of oncology and rare disease indications for development of drug candidates from our GSO technology. Our key considerations in identifying disease indications in our GSO program include: strong evidence that the disease is caused by a specific protein; clear criteria to identify a target patient population; biomarkers for early assessment of clinical proof of concept; a targeted therapeutic mechanism for action; and unmet medical need to allow for a rapid development path to approval. We are planning to conduct disease model studies and begin IND-enabling development programs in each of the first two disease indications selected for further development in our GSO program in the second half of 2015.".........This management team is laser-beamed on getting everything right the first time. Hence, money backers like GS, JPM, BB, Fidelity, Blackrock, and whoever is accumulating this week.